Online inquiry

IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1519MR)

This product GTTS-WQ1519MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1519MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3455MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ2431MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ7053MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ14568MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ13007MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ6469MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ10224MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ13744MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW